ACT

Arch Biopartners Inc. ("Arch" or the "Company") (CNSX:ACH)(OTC:FOIFF) and its
subsidiary Arch Cancer Therapeutics ("ACT") today announced Arch scientists Dr.
Donna Senger and Dr. Stephen Robbins have been awarded $561,251 of peer reviewed
research funding to support ongoing work in the area of malignant glioma and the
development of brain tumour cell targeting technology. 


This funding award is from a recent Alberta Cancer Research Operating Grants
Competition sponsored by Alberta Innovates - Health Solutions (previously the
Alberta Heritage Foundation for Medical Research). The funds are scheduled to be
released from the Alberta Cancer Prevention Legacy Fund in three annual tranches
starting July 1, 2011, pending final administrative approval from the Minister
of Alberta Health and Wellness.


The money will support work for the project entitled "Characterization and
Therapeutic Targeting of p75NTR in Glioma Tumourigenesis", that includes studies
to further define and develop peptides that target, locate and inhibit invasive
glioma cells. These studies are in addition to recently completed proof of
principle studies in the area of targeting brain tumour initiating cells which
are currently undergoing peer review.


About Arch Cancer Therapeutics 

ACT is an Alberta corporation wholly owned by Arch Biopartners. ACT's objective
is to develop non-invasive diagnostic and therapeutic molecules for brain cancer
utilizing new and innovative approaches. 


Despite intensive research over the past 30 years, clinical outcomes for
patients with malignant glioma have not changed substantially with average
survival rates remaining at a dismal 12-15 months. ACT's proprietary molecules
are specialized peptides that identify and target brain tumor initiating cells
("BTIC") and invasive brain cancer cells, two disease reservoirs that are not
normally seen using current state of the art diagnostic imaging techniques. 


About Arch Biopartners

Arch Biopartners is a portfolio based biotechnology company established to
developing early stage proprietary technology for sale to pharmaceutical and
industrial companies.


The Company's website address is: www.archbiopartners.com.

For more information on the Company, please consult the other public documents
filed on SEDAR at www.sedar.com. 


Forward-Looking Statements 

All statements, other than statements of historical fact, in this news release
are forward looking statements that involve various risks and uncertainties,
including, without limitation, statements regarding the future plans and
objectives of the Company. There can be no assurance that such statements will
prove to be accurate. Actual results and future events could differ materially
from those anticipated in such statements. These and all subsequent written and
oral forward-looking statements are based on the estimates and opinions of
management on the dates they are made and are expressly qualified in their
entirety by this notice. The Company assumes no obligation to update
forward-looking statements should circumstances or management's estimates or
opinions change.

(TSXV:ACT)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024

(TSXV:ACT)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024